Penserra Capital Management LLC Sells 91,424 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Penserra Capital Management LLC lowered its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 19.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 383,836 shares of the company’s stock after selling 91,424 shares during the quarter. Penserra Capital Management LLC owned approximately 0.18% of Hims & Hers Health worth $7,069,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Renaissance Technologies LLC raised its position in shares of Hims & Hers Health by 113.1% in the second quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock worth $121,936,000 after buying an additional 3,205,108 shares in the last quarter. Farallon Capital Management LLC boosted its position in shares of Hims & Hers Health by 3,890.5% during the 1st quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock valued at $25,928,000 after acquiring an additional 1,634,000 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund boosted its position in shares of Hims & Hers Health by 164.1% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 528,142 shares of the company’s stock valued at $10,663,000 after acquiring an additional 328,142 shares during the last quarter. State of Michigan Retirement System grew its holdings in shares of Hims & Hers Health by 177.8% during the second quarter. State of Michigan Retirement System now owns 500,000 shares of the company’s stock worth $10,095,000 after purchasing an additional 320,000 shares in the last quarter. Finally, Carnegie Investment Counsel bought a new position in shares of Hims & Hers Health in the third quarter worth approximately $5,531,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Stock Up 4.9 %

Shares of HIMS opened at $25.33 on Monday. The firm has a fifty day simple moving average of $20.55 and a two-hundred day simple moving average of $19.31. Hims & Hers Health, Inc. has a twelve month low of $8.02 and a twelve month high of $30.44. The stock has a market capitalization of $5.53 billion, a P/E ratio of 57.57 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. The company had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. Hims & Hers Health’s revenue was up 77.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.04) EPS. Sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have commented on HIMS shares. Piper Sandler reissued a “neutral” rating and issued a $21.00 price target (up previously from $18.00) on shares of Hims & Hers Health in a research note on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, November 6th. Imperial Capital cut Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. TD Cowen reaffirmed a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Finally, Needham & Company LLC began coverage on Hims & Hers Health in a report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price objective for the company. One analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $20.71.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, COO Melissa Baird sold 58,750 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $21.04, for a total transaction of $1,236,100.00. Following the transaction, the chief operating officer now owns 630,166 shares in the company, valued at approximately $13,258,692.64. This represents a 8.53 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Andrew Dudum sold 188,888 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total value of $2,750,209.28. Following the completion of the transaction, the chief executive officer now owns 33,502 shares of the company’s stock, valued at approximately $487,789.12. The trade was a 84.94 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,056,183 shares of company stock worth $21,501,682 over the last quarter. 17.71% of the stock is owned by corporate insiders.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.